Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by AEGON ASSET MANAGEMENT UK Plc

AEGON ASSET MANAGEMENT UK Plc lessened its holdings in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 3.4% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 652,772 shares of the biotechnology company's stock after selling 23,029 shares during the period. AEGON ASSET MANAGEMENT UK Plc owned 0.84% of Veracyte worth $19,342,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. GAMMA Investing LLC grew its position in shares of Veracyte by 4,351.0% during the first quarter. GAMMA Investing LLC now owns 19,273 shares of the biotechnology company's stock valued at $571,000 after purchasing an additional 18,840 shares in the last quarter. Versant Capital Management Inc lifted its holdings in shares of Veracyte by 1,267.6% in the 1st quarter. Versant Capital Management Inc now owns 930 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 862 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Veracyte in the 4th quarter valued at about $324,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Veracyte in the 4th quarter valued at about $6,990,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Veracyte in the 4th quarter valued at about $64,000.

Analyst Ratings Changes

VCYT has been the subject of several analyst reports. UBS Group decreased their price objective on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Stephens reissued an "overweight" rating and issued a $45.00 price objective on shares of Veracyte in a research note on Wednesday, March 26th. Needham & Company LLC decreased their price objective on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Craig Hallum initiated coverage on shares of Veracyte in a research note on Thursday, March 20th. They issued a "buy" rating and a $45.00 price objective for the company. Finally, Guggenheim decreased their price objective on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Veracyte has a consensus rating of "Moderate Buy" and an average price target of $40.90.

Veracyte Trading Up 1.8%

VCYT stock traded up $0.48 during mid-day trading on Friday, reaching $27.46. The company's stock had a trading volume of 996,187 shares, compared to its average volume of 907,705. The stock has a market cap of $2.15 billion, a PE ratio of -183.07 and a beta of 2.14. Veracyte, Inc. has a fifty-two week low of $19.73 and a fifty-two week high of $47.32. The company's 50 day moving average is $29.62 and its two-hundred day moving average is $35.99.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.